APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Meningococcal Disease Treatment Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Meningococcal Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Meningococcal Disease Treatment market include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Meningococcal Disease Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningococcal Disease Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningococcal Disease Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Meningococcal Disease Treatment market.

Meningococcal Disease Treatment Segment by Company

Walvax Biotechnology Co.,Ltd.

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Beijing Minhai Biological Technology Co.,Ltd.

CanSino Biologics Inc.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

GlaxoSmithKline

Chengdu Institute of Biology

Sanofi Pasteur

Meningococcal Disease Treatment Segment by Type

Antibiotics

Vaccines

Meningococcal Disease Treatment Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Meningococcal Disease Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Meningococcal Disease Treatment key companies, revenue, market share, and recent developments.

3. To split the Meningococcal Disease Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Meningococcal Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Meningococcal Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Meningococcal Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Disease Treatment industry.

Chapter 3: Detailed analysis of Meningococcal Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Meningococcal Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Meningococcal Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Meningococcal Disease Treatment Industry Trends Table 2. Meningococcal Disease Treatment Industry Drivers Table 3. Meningococcal Disease Treatment Industry Opportunities and Challenges Table 4. Meningococcal Disease Treatment Industry Restraints Table 5. Global Meningococcal Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Meningococcal Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Meningococcal Disease Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Meningococcal Disease Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Meningococcal Disease Treatment Company, Product Type & Application Table 10. Global Meningococcal Disease Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Meningococcal Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antibiotics Table 15. Significant Companies of Vaccines Table 16. Global Meningococcal Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Meningococcal Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Meningococcal Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Meningococcal Disease Treatment Sales Value Share by Type (2021-2026) Table 20. Global Meningococcal Disease Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Drugstores Table 23. Significant Companies of Others Table 24. Global Meningococcal Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Meningococcal Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Meningococcal Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Meningococcal Disease Treatment Sales Value Share by Application (2021-2026) Table 28. Global Meningococcal Disease Treatment Sales Value Share by Application (2027-2032) Table 29. Global Meningococcal Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Meningococcal Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Meningococcal Disease Treatment Sales Value Share by Region (2021-2026) Table 32. Global Meningococcal Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Meningococcal Disease Treatment Sales Value Share by Region (2027-2032) Table 34. Global Meningococcal Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Meningococcal Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Meningococcal Disease Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Meningococcal Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Meningococcal Disease Treatment Sales Value Market Share by Country (2027-2032) Table 39. Walvax Biotechnology Co.,Ltd. Company Information Table 40. Walvax Biotechnology Co.,Ltd. Business Overview Table 41. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 43. Walvax Biotechnology Co.,Ltd. Recent Development Table 44. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 45. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 46. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 48. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Meningococcal Disease Treatment Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Sharp & Dohme Company Information Table 55. Merck Sharp & Dohme Business Overview Table 56. Merck Sharp & Dohme Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio Table 58. Merck Sharp & Dohme Recent Development Table 59. Beijing Minhai Biological Technology Co.,Ltd. Company Information Table 60. Beijing Minhai Biological Technology Co.,Ltd. Business Overview Table 61. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 63. Beijing Minhai Biological Technology Co.,Ltd. Recent Development Table 64. CanSino Biologics Inc. Company Information Table 65. CanSino Biologics Inc. Business Overview Table 66. CanSino Biologics Inc. Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio Table 68. CanSino Biologics Inc. Recent Development Table 69. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 70. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 71. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio Table 73. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Meningococcal Disease Treatment Product Portfolio Table 78. Pfizer Recent Development Table 79. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 80. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 81. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio Table 83. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 84. GlaxoSmithKline Company Information Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline Meningococcal Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio Table 88. GlaxoSmithKline Recent Development Table 89. Chengdu Institute of Biology Company Information Table 90. Chengdu Institute of Biology Business Overview Table 91. Chengdu Institute of Biology Meningococcal Disease Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio Table 93. Chengdu Institute of Biology Recent Development Table 94. Sanofi Pasteur Company Information Table 95. Sanofi Pasteur Business Overview Table 96. Sanofi Pasteur Meningococcal Disease Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio Table 98. Sanofi Pasteur Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Meningococcal Disease Treatment Product Image Figure 2. Global Meningococcal Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antibiotics Image Figure 8. Vaccines Image Figure 9. Global Meningococcal Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Meningococcal Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Meningococcal Disease Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Drugstores Image Figure 14. Others Image Figure 15. Global Meningococcal Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Meningococcal Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Meningococcal Disease Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Meningococcal Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Meningococcal Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Meningococcal Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Meningococcal Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Meningococcal Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Meningococcal Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Meningococcal Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Meningococcal Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Meningococcal Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Meningococcal Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Meningococcal Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Meningococcal Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Antibiotics
  • Vaccines
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Walvax Biotechnology Co.,Ltd.
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Beijing Minhai Biological Technology Co.,Ltd.
  • CanSino Biologics Inc.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • GlaxoSmithKline
  • Chengdu Institute of Biology
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Meningococcal Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Meningococcal Disease Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Meningococcal Disease Treatment Market Dynamics
  1. 2.1 Meningococcal Disease Treatment Industry Trends
  2. 2.2 Meningococcal Disease Treatment Industry Drivers
  3. 2.3 Meningococcal Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Treatment Industry Restraints
3 Meningococcal Disease Treatment Market by Company
  1. 3.1 Global Meningococcal Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Meningococcal Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Meningococcal Disease Treatment Company Ranking (2024-2026)
  4. 3.4 Global Meningococcal Disease Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Meningococcal Disease Treatment Company Product Type and Application
  6. 3.6 Global Meningococcal Disease Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Meningococcal Disease Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Meningococcal Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Meningococcal Disease Treatment Market by Type
  1. 4.1 Meningococcal Disease Treatment Type Introduction
  2. 4.1.1 Antibiotics
  3. 4.1.2 Vaccines
  4. 4.2 Global Meningococcal Disease Treatment Sales Value by Type
  5. 4.2.1 Global Meningococcal Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Meningococcal Disease Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Meningococcal Disease Treatment Sales Value Share by Type (2021-2032)
5 Meningococcal Disease Treatment Market by Application
  1. 5.1 Meningococcal Disease Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Meningococcal Disease Treatment Sales Value by Application
  6. 5.2.1 Global Meningococcal Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningococcal Disease Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Meningococcal Disease Treatment Sales Value Share by Application (2021-2032)
6 Meningococcal Disease Treatment Regional Value Analysis
  1. 6.1 Global Meningococcal Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Meningococcal Disease Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Meningococcal Disease Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Meningococcal Disease Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Meningococcal Disease Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Meningococcal Disease Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Meningococcal Disease Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Meningococcal Disease Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Meningococcal Disease Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Meningococcal Disease Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Meningococcal Disease Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Meningococcal Disease Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Meningococcal Disease Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Meningococcal Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Meningococcal Disease Treatment Country-level Value Analysis
  1. 7.1 Global Meningococcal Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Meningococcal Disease Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Meningococcal Disease Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Meningococcal Disease Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Meningococcal Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Meningococcal Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Meningococcal Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Walvax Biotechnology Co.,Ltd.
  2. 8.1.1 Walvax Biotechnology Co.,Ltd. Company Information
  3. 8.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
  4. 8.1.3 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  6. 8.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
  7. 8.2 Apeloa Pharmaceutical Co.,Ltd.
  8. 8.2.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  9. 8.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  10. 8.2.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  12. 8.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck Sharp & Dohme
  20. 8.4.1 Merck Sharp & Dohme Company Information
  21. 8.4.2 Merck Sharp & Dohme Business Overview
  22. 8.4.3 Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
  24. 8.4.5 Merck Sharp & Dohme Recent Developments
  25. 8.5 Beijing Minhai Biological Technology Co.,Ltd.
  26. 8.5.1 Beijing Minhai Biological Technology Co.,Ltd. Company Information
  27. 8.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
  28. 8.5.3 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  30. 8.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
  31. 8.6 CanSino Biologics Inc.
  32. 8.6.1 CanSino Biologics Inc. Company Information
  33. 8.6.2 CanSino Biologics Inc. Business Overview
  34. 8.6.3 CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
  36. 8.6.5 CanSino Biologics Inc. Recent Developments
  37. 8.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 8.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 8.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 8.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
  42. 8.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  50. 8.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  51. 8.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  52. 8.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
  54. 8.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Chengdu Institute of Biology
  62. 8.11.1 Chengdu Institute of Biology Company Information
  63. 8.11.2 Chengdu Institute of Biology Business Overview
  64. 8.11.3 Chengdu Institute of Biology Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
  66. 8.11.5 Chengdu Institute of Biology Recent Developments
  67. 8.12 Sanofi Pasteur
  68. 8.12.1 Sanofi Pasteur Company Information
  69. 8.12.2 Sanofi Pasteur Business Overview
  70. 8.12.3 Sanofi Pasteur Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
  72. 8.12.5 Sanofi Pasteur Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst